GLP1R and Alzheimer disease: Continuous use of GLP1 receptor agonists versus DPP4 inhibitors did not show statistically significant estimates for AD (HR [95% CI]: 0.84 [0.60–1.19]) and VD (HR [95% CI]: 0.71 [0.47–1.07]).